Zacks: Dipexium Pharmaceuticals Inc. (DPRX) Given Consensus Recommendation of “Strong Buy” by Brokerages
Shares of Dipexium Pharmaceuticals Inc. (NASDAQ:DPRX) have earned an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1 year consensus target price of $27.25 for the company and are forecasting that the company will post ($0.55) earnings per share for the current quarter, according to Zacks. Zacks has also assigned Dipexium Pharmaceuticals an industry rank of 111 out of 265 based on the ratings given to its competitors.
Separately, Zacks Investment Research raised shares of Dipexium Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, July 8th.
Dipexium Pharmaceuticals (NASDAQ:DPRX) opened at 14.80 on Monday. The company’s 50-day moving average is $14.10 and its 200-day moving average is $11.60. The stock’s market capitalization is $153.89 million. Dipexium Pharmaceuticals has a 12 month low of $6.04 and a 12 month high of $17.75.
Dipexium Pharmaceuticals (NASDAQ:DPRX) last issued its earnings results on Thursday, August 4th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.54) by $0.02. Equities analysts anticipate that Dipexium Pharmaceuticals will post ($2.10) earnings per share for the current year.
Hedge funds have recently made changes to their positions in the stock. Lombard Odier Asset Management USA Corp purchased a new stake in shares of Dipexium Pharmaceuticals during the second quarter worth $1,507,000. Goldman Sachs Group Inc. purchased a new stake in shares of Dipexium Pharmaceuticals during the first quarter worth $1,062,000. Emerald Acquisition Ltd. purchased a new stake in shares of Dipexium Pharmaceuticals during the second quarter worth $854,000. Raymond James & Associates purchased a new stake in shares of Dipexium Pharmaceuticals during the second quarter worth $312,000. Finally, Timpani Capital Management LLC increased its stake in shares of Dipexium Pharmaceuticals by 45.4% in the second quarter. Timpani Capital Management LLC now owns 64,124 shares of the company’s stock worth $635,000 after buying an additional 20,014 shares in the last quarter. Institutional investors and hedge funds own 24.78% of the company’s stock.
About Dipexium Pharmaceuticals
Dipexium Pharmaceuticals, Inc is a late-stage pharmaceutical company. The Company is focused on the development and commercialization of Locilex (pexiganan cream 0.8%), a first-in-class, broad spectrum, topical antibiotic. Locilex is focused on the treatment of mild infections of diabetic foot ulcers (Mild DFI).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Dipexium Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dipexium Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.